Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyvaso in Exercise-induced Pulmonary Hypertension
NCT07116681Phase 1Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Oct 2025
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of treprostinil in pulmonary hypertension (PH), sponsored by University of California, San Diego. Primary endpoint: Stroke volume augmentation at 30 minutes. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07116681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116681.